Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial.

Fiche publication

Date publication

décembre 2024

Journal

ESC heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARIE Pierre-Yves , Pr MEYER Nicolas

Tous les auteurs :
Roncalli J, Roubille F, Meyer N, Pompilio G, Leroux L, Henon P, Trebuchet G, Criquet A, de Kalbermatten M, Saloux E, Manrique A, Marie PY, Bhatt DL, Solomon SD, Montalescot G, Newby DE, Zannad F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39676512

Résumé

The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes. The dose of CD34+ cells and the route of administration are two important factors that will determine the clinical effectiveness of the approach, provided it is robust and feasible. Here, we describe the rationale and design of the multicentre open-label randomized controlled phase I/IIb trial evaluating the safety and the likelihood of efficacy of transendocardial expanded CD34+ cell administration in patients presenting with AMI and a reduced LV ejection fraction.